The Biohazardous Agent Reference Document (BARD) is a general guidance resource that reviews and summarizes the nature of a pathogen or biotoxin, and offers safety requirements for work with the agent

in the laboratory. The BARD may replace the formal SOPs used in conjunction with some IBC registrations.

The BARD is provided as an additional guidance tool, and is not a substitute for a risk assessment, biosafety training, lab-specific training, or a formal [IBC master protocol registration](https://www.uvm.edu/rpo/biosafety-oversight). This document should be readily available in the laboratory, and it is the responsibility of the Laboratory Supervisor or Principal Investigator to ensure that all personnel have read, understood, and signed the document. The BARD is for informational purposes only, and is not intended to be a substitute for professional medical advice, diagnosis, or treatment.

Please consult a health care provider for any medical questions or concerns.

**INSTRUCTIONS**

1. **Review the information contained in this document.**
2. **Add any necessary information that is specific to your work in the laboratory (such as strain-specific information). Please be sure that the track changes function is turned on to indicate any changes that you make.**
3. **Instruct all personnel to review the BARD and sign the last page, indicating that they have**

**read and understood the information.**

1. **Submit the BARD along with your IBC master protocol registration, amendment, or continuing review.**

|  |
| --- |
| **Characteristics** |
| ***Morphology*** | Enveloped viruses, commonly used to deliver genetic information into DNA of host cells. |
| ***Strain Specific******Characteristics*** | Vector systems exist with multiple safety features such as segregation of vector and packaging functions on separate plasmids, or deletions of genes essential to replication. The resulting viruses can only execute one cycle of infecting a target cell and integration of transferrable DNA into the host cell’s genome.  |

|  |
| --- |
| **health hazards** |
| ***Host Range*** | Humans and non-human primates are natural hosts. Pseudotyping the envelope protein can alter the host range. |
| ***Modes of Transmission*** | Mucous membrane contact, ingestion, needlestick or other injury, contact with non‐ intact skin  |
| ***Signs and Symptoms*** | Fever, fatigue, weight loss, immunological and neurological disease, insertional mutagenesis  |
| ***Infectious Dose*** | Unknown |
| ***Incubation Period*** | 1 – 6 months |

|  |
| --- |
| **Medical precautions / treatment** |
| ***Prophylaxis*** | None available |
| ***Vaccines*** | None available |
| ***Treatment*** | Anti-retroviral PEP as indicated by physician |
| ***Surveillance*** | Monitor for symptoms and test using serology or western blot |
| ***UVM IBC Requirements*** | Report any exposures or signs and symptoms to your supervisor |
| ***Additional Medical Precautions*** |  |

|  |
| --- |
| **laboratory hazards** |
| ***Laboratory Acquired Infections*** | 6 reported lab-acquired infections |
| ***Sources*** | Blood, tissues, cerebrospinal fluid, nasopharynx secretions, and cells from infected humans, animals and infected cell lines.  |

|  |
| --- |
| **Containment Requirements** |
| ***BSL - 2*** | Manipulation of known or potentially infected clinical samples and cell cultures of laboratory adapted strains (RG2)  |
| ***BSL - 3*** |  |
| ***ABSL - 2*** | Work with animals infected with risk group 2 strains. Animals infected with replication incompetent strains may be moved to ABSL‐1 after 72 hours. If the strain is replication competent, animals must remain at ABSL‐2  |
| ***ABSL - 3*** |  |
| ***Aerosol generating activities*** | Centrifugation, homogenizing, vortexing or stirring, changing of animal cages, animal surgeries, cell sorting, pipetting, pouring liquids, sonicating, loading syringes  |
| ***Primary containment device (BSC)*** | Use for all work with infectious or potentially infectious material, loading and unloading centrifuge rotors.  |

|  |
| --- |
| **exposure procedures** |
| ***Mucous membranes*** | Flush eyes, mouth or nose for 15 minutes at eyewash station. |
| ***Other exposures*** | Wash area with soap and water for 15 minutes |
| ***Medical Follow-Up*** | Contact UVMMC Infectious Disease Dept. directly at **(802) 847-2700** for immediate assistance. Bring this document with you if seeking medical care. |
| ***Reporting*** | Report all exposures or near misses to:1. Your immediate Supervisor
2. The UVM Biosafety Officer at **(802) 777-9471** and Risk Management at **6-3242**
3. Risk Management and Safety; <https://www.uvm.edu/riskmanagement/incident-claim-reporting-procedures>
 |

|  |
| --- |
| **Personal protective equipment (PPE)** |
| ***Minimum PPE Requirements*** | Nitrile gloves, lab coat, appropriate eye/face protection. Wash hands after removing gloves. |
| ***Additional Precautions*** ***(Risk assessment dependent)*** | Sharps use strictly limited. Open wounds or cuts should be allowed to scab over before entering the laboratory, and should then be covered with waterproof dressings.  |

|  |
| --- |
| **Viability** |
| ***Disinfection*** | Susceptible to fresh 10% bleach, 2% glutaraldehyde, formaldehyde; All with contact time of 10 minutes |
| ***Inactivation*** | Inactivated by heat above 56°C for at least 30 minutes  |
| ***Survival Outside Host*** | Drying causes 90 – 99% reduction in viability after several hours  |

|  |
| --- |
| **Spill clean up procedures** |
| ***Small Spill*** | Notify others working in the lab. Allow aerosols to settle. Don appropriate PPE. Cover area of the spill with paper towels and apply approved disinfectant, working from the perimeter towards the center. Allow 30 minutes of contact time before clean up and disposal. Dispose in double biowaste bags and biobox. |
| ***Large Spill*** | **Inside of a lab:** Call UVM Service Operations at 656-2560 and press option 1 to speak to a dispatcher. Ask them to page Risk Management and Safety. **Outside of a lab:** Pull the nearest fire alarm and evacuate the building. Wait out front of the building for emergency responders to arrive. |

|  |
| --- |
| **Student / Employee Name SIGNATURE DATE** |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |

***Biosafety Review:***

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Jeff LaBossiere, Biological Safety Officer

|  |
| --- |
| **References** |
| Applied Biosafety  | <http://journals.sagepub.com/doi/pdf/10.1177/153567600400900203> |
| BMBL | <https://www.cdc.gov/biosafety/publications/bmbl5/> |
| ASM Journal of Virology  | <https://jvi.asm.org/content/72/2/994> |
| Journal of Biomedicine and Biotechnology | <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC179763/> |

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Date